Cannabis Reform Races Forward in Some States While Others Reach for the Handcuffs

A Nation Divided: Cannabis Reform Races Forward in Some States While Others Reach for the Handcuffs

If 2024 was the year cannabis optimists declared momentum unstoppable, 2026 is the year the map got complicated. The week of May 4–10 captured the contradictions of the current legislative moment in unusually sharp focus: a Southern state filed a bill to put cannabis decriminalization before voters, another moved toward jailing consumers, and federal policymakers left a time bomb ticking under an entire product category while a retail giant doubled down anyway.

The most significant state-level development of the week came out of North Carolina, where Senate Bill 1072 — filed May 4 and cleared for its first reading by May 5 — would put cannabis decriminalization and medical use rights directly to North Carolina voters through a constitutional amendment process. The bill addresses the right to personal possession of limited cannabis quantities and medical use, bypassing the legislative gridlock that has stalled cannabis reform in the state for years by letting citizens vote on the question directly. North Carolina remains one of the few Southeastern states with neither a medical nor a decriminalization framework, and the bill's introduction signals that even in traditionally resistant states, the political math is shifting.

Simultaneously, Louisiana took the opposite road. A bill that would impose jail time for cannabis consumers advanced toward the state Senate floor during the week, a striking rebuke in a region where cannabis sentiment has been slowly liberalizing. Louisiana's move reflects a broader counter-trend that policy analysts at the Rockefeller Institute of Government have been tracking in 2026: a genuine pushback movement that seeks to roll back existing decriminalization frameworks, restrict cannabis markets, or block new legalization efforts from reaching voters. Observers at the Institute describe 2026 as a year not of inevitable progress but of genuine contestation — with reform and restriction moving forward in parallel, sometimes in the same week.

In Idaho, the Natural Medicine Alliance's submission of more than 100,000 signatures at the end of April triggered a verification process that was underway throughout this week, with state officials working through the count to determine whether a medical cannabis measure qualifies for the November ballot. Idaho is one of the last remaining states with a near-total cannabis prohibition, and getting a measure to voters would be a landmark development regardless of the eventual outcome. The signature verification deadline falls in late May, meaning the cannabis world will know within weeks whether Idaho's first formal ballot measure has legs.

Meanwhile, Ohio continued generating controversy from a different direction: state lawmakers earlier this year enacted Senate Bill 56, which critics say makes significant and damaging changes to the voter-approved adult-use cannabis law passed at the ballot box in 2023. Cannabis advocates argue the bill undermines the will of Ohio voters; supporters contend it tightens regulatory guardrails. The legal and political fight over SB 56 is ongoing, and it represents a pattern that has become disturbingly familiar: voters legalize cannabis, and state legislatures then rewrite the implementation rules in ways that narrow or reshape the original measure.

On the federal side, the week's most consequential ongoing story remained the aftershocks of the April 23 DOJ Final Order that moved state-licensed medical cannabis to Schedule III. The DEA's expedited registration window — in which medical cannabis operators can apply for federal compliance status and continue operating while applications are processed — is now running, with the 60-day clock ticking. Operators who miss the window risk being caught in regulatory ambiguity. The DEA has separately announced that a formal administrative hearing on broader marijuana rescheduling will begin June 29 — a hearing that could determine whether adult-use cannabis eventually follows the medical rescheduling path. Written participation requests are due by May 28.

The hemp side of federal policy may be even more immediately consequential for consumers. Earlier this year, Congress passed and President Trump signed legislation that will effectively recriminalize hemp-derived products containing more than 0.4 milligrams of THC per container — a threshold so low it would sweep virtually the entire hemp-derived THC beverage market off shelves. That law is scheduled to take effect in November 2026. Bipartisan congressional efforts to delay the ban have not gained traction with leadership, which means the clock is running on a product category that has grown into a multi-billion-dollar market through mass retail channels. The implications for consumers, retailers, and hemp farmers are enormous — and the political calculus for delaying the ban remains unclear.

What the week made plain is that cannabis policy in 2026 is not a single story. It is dozens of overlapping stories — medical access bills and re-criminalization moves, federal reclassifications and impending product bans, voter signature drives and legislative rewrites. The landscape is genuinely uncertain, and the next six months of rulemaking, hearings, ballot decisions, and court rulings will matter enormously. Anyone who tells you the arc of cannabis policy bends inevitably toward liberalization hasn't been watching state legislatures lately.